Skip to main content
. 2018 Jan 12;66(6):403–414. doi: 10.1369/0022155417750838

Table 3.

Expression of mTOR, rpS6 and Its Phosphorylated Forms, and RAPTOR in Gliomas.

Reference Cohort Protein evaluated Survival Difference with our study
Korkolopoulou et al.17 25 DA, 12 AA, 71 GBM Manual HSCORE system. pmTOR HSCORE increases with grade. Mann–Whitney analysis. pmTOR correlated with disease-free survival. Analysis grouped grades II, III, and IV in the same analysis. In our study, statistical analyses were based on ANOVA and survival was performed in GBMs as a single group.
Li et al.18 27 PA + DA, 24 AA, 36 GBM Manual HSCORE system. pmTOR increases with grade. Grouped grades I and II, no indication of statistical test. In our study, statistical analyses were based on ANOVA and different grades were not grouped together for analysis.
Pelloski et al.21 268 GBM + 60 GBM for validation Manually classified pmTOR positive or negative pmTOR was associated to worse survival in GBM in univariate analysis. Cutoff points for the survival
Thorarinsdottir et al.23 42 PA, 21 DA, 13 AA, 9 GBM pediatric Manual HSCORE. pmTOR expression increases with grade. No relationship with survival Age of the cohort. Thorarinsdottir et al. included patients below 21 years of age.
Annovazzi et al.12 34 GBM, 10 AA, 10 DA, and 10 OL Manual three-tier scale. pmTOR and p(240–244)S6 increase with grade. No indication of statistical test used. Nuclear staining of pmTOR. No correlation with survival in GBMs. There is no indication of the cutoff values used for the survival analysis. In our study, automated immunohistochemistry analysis and continuous HSCORE classification were used to calculate cutoff point for the survival analysis.
Hütt-Cabezas et al.15 177 PA Four-tier scale. Moderate/strong mTOR positivity in 47% of cases, 59% for p(235–236)S6, and 63% for RAPTOR. No relationship with survival Composition of the cohort. Hütt-Cabezas et al included PAs only.
Rodriguez et al.32 43 PA, 24 aggressive PA, 25 histologically anaplastic PA Four-tier manual score. p(235–236)S6 score increases in aggressive PAs. Composition of the cohort. Rodriguez et al. included PAs only.
Jentoft et al.16 16 PA, 6 LGSI, 1 DA, 1 GG, 39 sporadic PA Four-tier manual score. p(235–236)S6 positivity in 33% sporadic PA. Composition of the cohort. Jentoft et al. included PAs only.
Mueller et al.20 Pediatric 25 PA, 7 DA, 7 AA, and 9 GBM Four-tier manual score. p(235–236)S6 and p(240–244)S6 increase with grade. No pS6 relationship with survival Age of the cohort. Mueller et al. included patients below 18 years of age.
Yang et al.33 16 DA, 35 AA, 45 GBM Manually classified in low or high. p(235–236)S6 increases with grade. pS6 expression was associated with a worse prognosis in univariate and multivariate analysis In our study, automated HSCORE was used to calculate cutoff. In Yang et al, criteria for classification were based on renal cell carcinoma literature.
McBride et al.19 22 DA, 16 OL e 7 mixed Four-tier manual score. p(235–236)S6 and p(240–244)S6 present in 76% of cases. Statistically significant inverse relationship between OS and p 235/236 and pSer-240. Composition of the cohort. McBride et al. included grade II astrocytomas only.

Abbreviations: DA, diffuse astrocytoma; AA, anaplastic astrocytoma; GBM, glioblastoma; PA, pilocytic astrocytoma; OL, oligodendroglioma; GG, ganglioglioma; LGSI, low grade astrocytoma subtype indeterminate; OS, overall survival.